Abstract 835P
Background
Very old patients usually have various comorbidities, poor performance status and poor frailty. Therefore, as patients get aged, they generally tend to be intolerable to intensive chemotherapy. In Japan, sobuzoxane, which is an oral anticancer drug that inhibits DNA topoisomerase II, was approved in 1994 and has been used for patients with lymphoma. Thus far, we have treated lymphoma patients with an attenuated chemotherapy, oral sobuzoxane and etoposide plus rituximab (R-PVP).
Methods
We retrospectively analysed 30 patients aged 80 and over who were newly diagnosed with diffuse large B-cell lymphoma (DLBCL) and initially treated with R-PVP therapy from 2008 to 2022.
Results
The median age of the patients was 84 years (range, 80-93). The median number of Charlson Comorbidity Index (CCI) was 4 (range, 2-11). Median four doses of both sobuzoxane 400 mg and etoposide 25 mg were orally administered every other day per cycle, and rituximab 375 mg/m2 intravenously once. Patients received a median of six cycles of R-PVP at a four-week interval. With a median follow-up of 26.4 months (range, 5.4-72.9), median progression ‘free survival (PFS) and overall survival (OS) time was 13.9 and 32.0 months, with a 5-year PFS and OS rate of 24% (95% CI, 8-46%) and 28% (95% CI, 10-49%), respectively. The most frequent grade 3 or 4 adverse event was neutropaenia (53%). No deaths were documented due to the toxicities of the treatment. A multivariate logistic regression analysis revealed that serum LDH value of >=1.5x upper limit of normal was the only unfavourable variable for both PFS and OS in R-PVP therapy (PFS: hazard ratio (HR), 5.60; 95% CI, 1.64-19.11; p = 0.006; OS: HR, 4.83; 95% CI, 1.22-19.17; p = 0.025). In a cohort of 20 patients who underwent R-PVP and 25 R-miniCHOP over the past decade, using the Kaplan-Meier method, there were no statistical differences between the groups regarding PFS and OS (median PFS: R-PVP 9.3 months vs. R-miniCHOP 26.4 months, p = 0.307; median OS: R-PVP not reached (NR) vs. R-miniCHOP NR, p = 0.375).
Conclusions
Our findings may suggest that R-PVP therapy is one of safe and effective treatments for a subgroup of patients, i.e. those who have high CCI or low tumour burden, among untreated DLBCL patients aged over 80.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
947P - The efficacy and safety of cadonilimab combined with lenvatinib for first-line treatment of advanced hepatocellular carcinoma: A phase Ib/II clinical trial
Presenter: Li Bai
Session: Poster session 18
949P - Regorafenib combined with immunotherapy versus regorafenib as second-line therapy in patients with advanced hepatocellular carcinoma: A multicenter real-world study
Presenter: Bin-Kui Li
Session: Poster session 18
952P - Efficacy and safety of a PRospective, Observational trial of Lenvatinib cOmbined with transarterial chemoembolization (TACE) as initial treatment for advaNced staGe hepatocellular carcinoma (PROLONG): A multicenter, single-armed, real-world study
Presenter: Guoliang Shao
Session: Poster session 18
953P - Tislelizumab plus regorafenib as second-line therapy for unresectable hepatocellular carcinoma (uHCC): A single-arm, phase II trial
Presenter: Zhongchao Li
Session: Poster session 18
954P - Radiotherapy combined with tislelizumab plus anlotinib as first-line treatment for hepatocellular carcinoma: A single arm, phase II clinical trial
Presenter: Guishu wu
Session: Poster session 18
955P - IMMUNIB trial (AIO-HEP-0218/ass): A single-arm phase II study evaluating safety and efficacy of immunotherapy with nivolumab in combination with lenvatinib in advanced hepatocellular carcinoma
Presenter: Arndt Vogel
Session: Poster session 18
956P - Phase II study of adjuvant tislelizumab combined with interferon-α and active surveillance in hepatocellular carcinoma patients with microvascular invasion
Presenter: Yixiu Wang
Session: Poster session 18